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Background: Ajmaline is a pharmaceutical agent now administered globally for a variety of indications, particularly
investigation of suspected Brugada syndrome. There have been previous reports suggesting that repetitive use of
this agent may cause severe liver injury, but little evidence exists demonstrating the same effect after only a single
administration.
Case presentation: A 33-year-old man of Libyan origin with no significant past medical history underwent an
ajmaline provocation test for investigation of suspected Brugada syndrome. Three weeks later, he presented with
painless cholestatic jaundice which peaked in severity at eleven weeks after the test. Blood tests confirmed no
evidence of autoimmune or viral liver disease, whilst imaging confirmed the absence of biliary tract obstruction. A
liver biopsy demonstrated centrilobular cholestasis and focal rosetting of hepatocytes, consistent with a cholestatic
drug reaction. Over the course of the next few months, he began to improve clinically and biochemically, with
complete resolution by one year post-exposure.
Conclusion: Whilst ajmaline-related hepatotoxicity was well-recognised in the era in which the drug was administered
as a regular medication, clinicians should be aware that ajmaline may induce severe cholestatic jaundice even after a
single dose administration.
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Ajmaline is an alkaloid agent that was first isolated from
the roots of Rauwolfia serpentine [1], and is classified as
a class Ia antiarrhythmic. It has a number of different
clinical indications for its use, with the major one at
present being to elicit the characteristic ST segment
changes on electrocardiogram (ECG) in patients sus-
pected of having type 1 Brugada syndrome [2]. It has
been used previously as maintenance treatment for dif-
ferent arrhythmias including atrial fibrillation in patients
with Wolff-Parkinson-White syndrome and also in* Correspondence: b.mullish@imperial.ac.uk
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unless otherwise stated.patients with ventricular tachycardia [3]. These, however,
are now relatively rare indications for its use.
Although ajmaline administration appears to be gener-
ally safe, there have been previous reports of apparent
drug-induced liver injury (DILI) related to its use. Some
of these reports, however, were hampered by methodo-
logical flaws, and many of them were described in the
era prior to easily-accessible serological confirmation/
exclusion of other liver insults, e.g. chronic viral hepa-
titis. Furthermore, there is to date only very scant
evidence of ajmaline causing liver injury after only a sin-
gle administration, the predominant means in which the
drug is delivered at present. We here present an unusual
case of severe cholestatic jaundice occurring after only a
single administration of ajmaline.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Mullish et al. BMC Gastroenterology 2014, 14:60 Page 2 of 4
http://www.biomedcentral.com/1471-230X/14/60Case presentation
A 33-year-old man of Libyan origin was seen in cardiology
clinic for investigation of pre-syncope. He had a strong
family history of premature sudden death of unclear aeti-
ology. As part of his assessment, he underwent an ajmaline
provocation test, during which he had continuous ECG
monitoring. After administration of 80 mg (equivalent to
1 mg/kg) of ajmaline, his monitoring demonstrated 2:1
atrioventicular block before reversion back to normal sinus
rhythm. There had been no electrophysiological evidence
of a type 1 Brugada syndrome prior to the assessment be-
ing stopped. The man was asymptomatic and had no evi-
dence of arrhythmia during three hours of subsequent
observation, and was discharged home.
Three weeks later, the man presented with painless
jaundice, pruritus, nausea, dark urine and pale-coloured
stools to his family physician. He had no personal or fam-
ily history of liver disease and had not been jaundiced pre-
viously. He took no regular medications, and denied the
use of alcohol, recreational drugs or herbal/ traditional
therapies. Examination revealed jaundice and excoriation,
but neither hepatomegaly nor features of chronic liver dis-
ease. An ultrasound of his abdomen demonstrated a nor-
mal appearance to the liver parenchyma, with no biliary
dilatation. The common bile duct (CBD) measured 5 mm
in maximal diameter, and no gallstones were seen. There
was normal portal and hepatic venous flow. Sonographic0
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Figure 1 Summary of the patient’s laboratory data during the course o
Time point zero is equivalent to the date that ajmaline was given intravenously
Bili: Bilirubin.appearances of the pancreas, spleen and kidneys were nor-
mal. He was kept under review.
Ten weeks after the test, his jaundice and pruritus had
worsened, and he was admitted to hospital for investiga-
tion. His liver enzyme profile was abnormal on admission
and continued to deteriorate, peaking at day 81 after the
administration of ajmaline with ALT 90 U/L, AST 67 U/L,
ALP 309 U/L, GGT 120 U/L, and bilirubin 244 μmol/L
(see Figure 1); no biochemistry results from prior to his ill-
ness were available. His platelet count, eosinophil count,
prothrombin time and plasma albumin remained within
normal limits throughout. His hepatitis A, B, C and E ser-
ology were negative. An auto-antibody profile (including
anti-mitochondrial antibody, anti-smooth muscle anti-
body, anti-liver-kidney-muscle antibody, anti-nuclear and
anti-nuclear cytoplasmic antibodies) was negative, and his
serum markers of iron and copper metabolism normal. In-
flammatory markers and white cell count differentials were
normal, excluding underlying sepsis. A repeat ultra-
sound of his liver and biliary tree showed similar find-
ings to that performed previously. Magnetic resonance
cholangio-pancreatography (MRCP) confirmed a CBD
of normal calibre, with no filling defects detected at any
point in the biliary system. The patient underwent liver
biopsy for further assessment. This demonstrated normal
bile ducts, but striking centrilobular cholestasis and focal
rosetting of hepatocytes (Figure 2). The biopsy results200 250 300 350 400
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Figure 2 Liver biopsy from the patient. Marked centrilobular
cholestasis is present, with otherwise normal bile duct structure and
no evidence of hepatic fibrosis. Arrows indicate areas of cholestasis.
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the history of ajmaline administration had not been volun-
teered by the patient prior to the liver biopsy, and only
emerged subsequently after liaison between the patient’s
hepatologists and his family physician.
By nine days into his admission, his symptoms had
begun to improve and his biochemistry stabilised, and he
was discharged back to community care. When reviewed
three weeks later, his pruritus had completely resolved. By
one year after the initial exposure to ajmaline, his serum
bilirubin and liver enzymes had near normalised (Figure 1).
Conclusion
There is strong evidence that this man’s illness repre-
sented the unusual syndrome of ajmaline-related chole-
static jaundice. On the CIOS/RUCAM scale, a validated
scoring system for suspected drug-induced liver injury,
this patient scores 8, which is interpreted as ‘probable’
DILI [4,5]. This in conjunction with his histological find-
ings indicates that it is very likely this patient’s liver injury
was entirely ajmaline-induced, especially given the thor-
ough exclusion of other possible aetiologies.
Ajmaline-related liver injury, at the time of writing
this article, is not listed on the LiverTox website (www.
livertox.nih.gov) that has been recently founded by the
Liver Disease Research Branch of the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) in
collaboration with the National Library of Medicine (NLM)
[6]. Case studies have described an association between
repetitive ajmaline administration and liver injury, with the
typical pattern identified being that of an initial acute hepa-
titis followed by a prolonged period of cholestasis [7-9].
However, no previous histologically confirmed cases of DILI
following a single dose administration of ajmaline have been
described in the literature. A single case report of cholestaticjaundice after a single administration of the medication has
been described [10], but in this report biliary obstruction
was not formally excluded via magnetic resonance imaging
and the histological nature of the underlying injury was not
delineated and hence not definitively confirmed to be
secondary to this agent. This case describes a 54-year-
old woman who presented with cholestatic jaundice three
weeks after an ajmaline challenge, with a complete clinical
and biochemical recovery at four months post-exposure.
The time course and pattern of liver enzymes between the
administration of the drug, the onset of jaundice and the
recovery between our patient and the patient in the prior
case report are similar.
Research into possible mechanisms of ajmaline-related
cholestasis is limited, although immune precipitates within
bile canaliculi have been found on liver biopsy samples
taken from a patient with cholestasis after repetitive ajma-
line exposure [8]. This may be consistent with ajmaline
acting as a hapten when bound to proteins within the bile
canaliculi. There is now evidence that an individual’s sus-
ceptibility to an idiosyncratic drug-induced liver injury
may relate to a number of factors, including single nucleo-
tide polymorphisms within particular HLA subtypes
[11-13]. Ajmaline is metabolised by the cytochrome P450
enzyme 2D6. It is recognised that 71% of European Cau-
casians have functional alleles of this enzyme, whilst this is
only the case in approximately 50% of Asians and Africans
[14]. It may be the case in this patient that exposure to
ajmaline in the context of a non-functional CYP2D6 allele,
plus inheritance of a vulnerable HLA subtype, increased
this patient’s propensity to drug-related liver injury.
In conclusion, hepatologists, pathologists, toxicologists
and cardiologists should recognise the association between
even a single administration of ajmaline and prolonged
cholestatic jaundice with the presence of centrilobular
cholestasis histologically. This case also highlights the im-
portance of taking an accurate and thorough medica-
tion history from both the patient and his primary
physician, including single-dose agents that patients
may have been administered. It may be that patients
from Africa and Asia have an increased propensity to
this form of liver injury. Further research is needed to
try and elucidate the mechanistic pathway by which
ajmaline results in cholestasis.Consent
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